Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes

Spencer S. Watson, Mark Dane, Kwang-Yung Chin, Zuzana Tatarova, Moqing Liu, Tiera Liby, Wallace Thompson, Rebecca Smith, Michel Nederlof, Elmar Bucher, David Kilburn, Matthew Whitman, Damir Sudar, Gordon Mills, Laura Heiser, Oliver Jonas, Joe Gray, James Korkola

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Extrinsic signals are implicated in breast cancer resistance to HER2-targeted tyrosine kinase inhibitors (TKIs). To examine how microenvironmental signals influence resistance, we monitored TKI-treated breast cancer cell lines grown on microenvironment microarrays composed of printed extracellular matrix proteins supplemented with soluble proteins. We tested ~2,500 combinations of 56 soluble and 46 matrix microenvironmental proteins on basal-like HER2+ (HER2E) or luminal-like HER2+ (L-HER2+) cells treated with the TKIs lapatinib or neratinib. In HER2E cells, hepatocyte growth factor, a ligand for MET, induced resistance that could be reversed with crizotinib, an inhibitor of MET. In L-HER2+ cells, neuregulin1-β1 (NRG1β), a ligand for HER3, induced resistance that could be reversed with pertuzumab, an inhibitor of HER2-HER3 heterodimerization. The subtype-specific responses were also observed in 3D cultures and murine xenografts. These results, along with bioinformatic pathway analysis and siRNA knockdown experiments, suggest different mechanisms of resistance specific to each HER2+ subtype: MET signaling for HER2E and HER2-HER3 heterodimerization for L-HER2+ cells. We describe a powerful platform for discovery of microenvironment signals that influence drug responses. We show through application of the platform to HER2+ breast cancer cell lines that NRG1β and HGF suppress responses to lapatinib and neratinib in L-HER2+ and HER2E cells, respectively. We show that these differences are caused by differences in epigenomic status and regulatory pathway use between L-HER2+ and HER2E breast cancers. We also present evidence suggesting that microenvironment-mediated resistance to HER2-targeted tyrosine kinase inhibitors can be overcome in L-HER2+ cancers by co-treatment with pertuzumab, and in HER2E cancers by co-treatment with crizotinib or trametinib.

Original languageEnglish (US)
JournalCell Systems
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Protein-Tyrosine Kinases
Breast Neoplasms
Ligands
Cell Line
Hepatocyte Growth Factor
Extracellular Matrix Proteins
Computational Biology
Heterografts
Epigenomics
Small Interfering RNA
Neoplasms
Proteins
Pharmaceutical Preparations
crizotinib
lapatinib
pertuzumab
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide

Keywords

  • Crizotinib
  • Drug resistance
  • HER2+ breast cancer subtypes
  • HER3
  • HGF
  • Lapatinib
  • Microenvironment
  • Neratinib
  • NRG1β
  • Pertuzumab

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Cell Biology

Cite this

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. / Watson, Spencer S.; Dane, Mark; Chin, Kwang-Yung; Tatarova, Zuzana; Liu, Moqing; Liby, Tiera; Thompson, Wallace; Smith, Rebecca; Nederlof, Michel; Bucher, Elmar; Kilburn, David; Whitman, Matthew; Sudar, Damir; Mills, Gordon; Heiser, Laura; Jonas, Oliver; Gray, Joe; Korkola, James.

In: Cell Systems, 01.01.2018.

Research output: Contribution to journalArticle

Watson, SS, Dane, M, Chin, K-Y, Tatarova, Z, Liu, M, Liby, T, Thompson, W, Smith, R, Nederlof, M, Bucher, E, Kilburn, D, Whitman, M, Sudar, D, Mills, G, Heiser, L, Jonas, O, Gray, J & Korkola, J 2018, 'Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes', Cell Systems. https://doi.org/10.1016/j.cels.2018.02.001
Watson, Spencer S. ; Dane, Mark ; Chin, Kwang-Yung ; Tatarova, Zuzana ; Liu, Moqing ; Liby, Tiera ; Thompson, Wallace ; Smith, Rebecca ; Nederlof, Michel ; Bucher, Elmar ; Kilburn, David ; Whitman, Matthew ; Sudar, Damir ; Mills, Gordon ; Heiser, Laura ; Jonas, Oliver ; Gray, Joe ; Korkola, James. / Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. In: Cell Systems. 2018.
@article{4445fee3868c4e089a101b85004d94c9,
title = "Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes",
abstract = "Extrinsic signals are implicated in breast cancer resistance to HER2-targeted tyrosine kinase inhibitors (TKIs). To examine how microenvironmental signals influence resistance, we monitored TKI-treated breast cancer cell lines grown on microenvironment microarrays composed of printed extracellular matrix proteins supplemented with soluble proteins. We tested ~2,500 combinations of 56 soluble and 46 matrix microenvironmental proteins on basal-like HER2+ (HER2E) or luminal-like HER2+ (L-HER2+) cells treated with the TKIs lapatinib or neratinib. In HER2E cells, hepatocyte growth factor, a ligand for MET, induced resistance that could be reversed with crizotinib, an inhibitor of MET. In L-HER2+ cells, neuregulin1-β1 (NRG1β), a ligand for HER3, induced resistance that could be reversed with pertuzumab, an inhibitor of HER2-HER3 heterodimerization. The subtype-specific responses were also observed in 3D cultures and murine xenografts. These results, along with bioinformatic pathway analysis and siRNA knockdown experiments, suggest different mechanisms of resistance specific to each HER2+ subtype: MET signaling for HER2E and HER2-HER3 heterodimerization for L-HER2+ cells. We describe a powerful platform for discovery of microenvironment signals that influence drug responses. We show through application of the platform to HER2+ breast cancer cell lines that NRG1β and HGF suppress responses to lapatinib and neratinib in L-HER2+ and HER2E cells, respectively. We show that these differences are caused by differences in epigenomic status and regulatory pathway use between L-HER2+ and HER2E breast cancers. We also present evidence suggesting that microenvironment-mediated resistance to HER2-targeted tyrosine kinase inhibitors can be overcome in L-HER2+ cancers by co-treatment with pertuzumab, and in HER2E cancers by co-treatment with crizotinib or trametinib.",
keywords = "Crizotinib, Drug resistance, HER2+ breast cancer subtypes, HER3, HGF, Lapatinib, Microenvironment, Neratinib, NRG1β, Pertuzumab",
author = "Watson, {Spencer S.} and Mark Dane and Kwang-Yung Chin and Zuzana Tatarova and Moqing Liu and Tiera Liby and Wallace Thompson and Rebecca Smith and Michel Nederlof and Elmar Bucher and David Kilburn and Matthew Whitman and Damir Sudar and Gordon Mills and Laura Heiser and Oliver Jonas and Joe Gray and James Korkola",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cels.2018.02.001",
language = "English (US)",
journal = "Cell Systems",
issn = "2405-4712",
publisher = "Cell Press",

}

TY - JOUR

T1 - Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes

AU - Watson, Spencer S.

AU - Dane, Mark

AU - Chin, Kwang-Yung

AU - Tatarova, Zuzana

AU - Liu, Moqing

AU - Liby, Tiera

AU - Thompson, Wallace

AU - Smith, Rebecca

AU - Nederlof, Michel

AU - Bucher, Elmar

AU - Kilburn, David

AU - Whitman, Matthew

AU - Sudar, Damir

AU - Mills, Gordon

AU - Heiser, Laura

AU - Jonas, Oliver

AU - Gray, Joe

AU - Korkola, James

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Extrinsic signals are implicated in breast cancer resistance to HER2-targeted tyrosine kinase inhibitors (TKIs). To examine how microenvironmental signals influence resistance, we monitored TKI-treated breast cancer cell lines grown on microenvironment microarrays composed of printed extracellular matrix proteins supplemented with soluble proteins. We tested ~2,500 combinations of 56 soluble and 46 matrix microenvironmental proteins on basal-like HER2+ (HER2E) or luminal-like HER2+ (L-HER2+) cells treated with the TKIs lapatinib or neratinib. In HER2E cells, hepatocyte growth factor, a ligand for MET, induced resistance that could be reversed with crizotinib, an inhibitor of MET. In L-HER2+ cells, neuregulin1-β1 (NRG1β), a ligand for HER3, induced resistance that could be reversed with pertuzumab, an inhibitor of HER2-HER3 heterodimerization. The subtype-specific responses were also observed in 3D cultures and murine xenografts. These results, along with bioinformatic pathway analysis and siRNA knockdown experiments, suggest different mechanisms of resistance specific to each HER2+ subtype: MET signaling for HER2E and HER2-HER3 heterodimerization for L-HER2+ cells. We describe a powerful platform for discovery of microenvironment signals that influence drug responses. We show through application of the platform to HER2+ breast cancer cell lines that NRG1β and HGF suppress responses to lapatinib and neratinib in L-HER2+ and HER2E cells, respectively. We show that these differences are caused by differences in epigenomic status and regulatory pathway use between L-HER2+ and HER2E breast cancers. We also present evidence suggesting that microenvironment-mediated resistance to HER2-targeted tyrosine kinase inhibitors can be overcome in L-HER2+ cancers by co-treatment with pertuzumab, and in HER2E cancers by co-treatment with crizotinib or trametinib.

AB - Extrinsic signals are implicated in breast cancer resistance to HER2-targeted tyrosine kinase inhibitors (TKIs). To examine how microenvironmental signals influence resistance, we monitored TKI-treated breast cancer cell lines grown on microenvironment microarrays composed of printed extracellular matrix proteins supplemented with soluble proteins. We tested ~2,500 combinations of 56 soluble and 46 matrix microenvironmental proteins on basal-like HER2+ (HER2E) or luminal-like HER2+ (L-HER2+) cells treated with the TKIs lapatinib or neratinib. In HER2E cells, hepatocyte growth factor, a ligand for MET, induced resistance that could be reversed with crizotinib, an inhibitor of MET. In L-HER2+ cells, neuregulin1-β1 (NRG1β), a ligand for HER3, induced resistance that could be reversed with pertuzumab, an inhibitor of HER2-HER3 heterodimerization. The subtype-specific responses were also observed in 3D cultures and murine xenografts. These results, along with bioinformatic pathway analysis and siRNA knockdown experiments, suggest different mechanisms of resistance specific to each HER2+ subtype: MET signaling for HER2E and HER2-HER3 heterodimerization for L-HER2+ cells. We describe a powerful platform for discovery of microenvironment signals that influence drug responses. We show through application of the platform to HER2+ breast cancer cell lines that NRG1β and HGF suppress responses to lapatinib and neratinib in L-HER2+ and HER2E cells, respectively. We show that these differences are caused by differences in epigenomic status and regulatory pathway use between L-HER2+ and HER2E breast cancers. We also present evidence suggesting that microenvironment-mediated resistance to HER2-targeted tyrosine kinase inhibitors can be overcome in L-HER2+ cancers by co-treatment with pertuzumab, and in HER2E cancers by co-treatment with crizotinib or trametinib.

KW - Crizotinib

KW - Drug resistance

KW - HER2+ breast cancer subtypes

KW - HER3

KW - HGF

KW - Lapatinib

KW - Microenvironment

KW - Neratinib

KW - NRG1β

KW - Pertuzumab

UR - http://www.scopus.com/inward/record.url?scp=85043538000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043538000&partnerID=8YFLogxK

U2 - 10.1016/j.cels.2018.02.001

DO - 10.1016/j.cels.2018.02.001

M3 - Article

C2 - 29550255

AN - SCOPUS:85043538000

JO - Cell Systems

JF - Cell Systems

SN - 2405-4712

ER -